Amphastar Pharmaceuticals, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $10.5m
$4.5m -57.20%
($5.7m) -227.28%
$48.9m +952.89%
$1.4m -97.13%
$62.1m +4327.37%
$91.4m +47.12%
$137.5m +50.51%
$159.5m +15.98%
$98.1m -38.51%
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($6.7m) $46.5m $1.1m $63.3m $91.4m $137.5m $159.5m $98.1m
Net Income (Loss) Attributable to Noncontrolling Interest ($922k) ($2.4m) ($306k) $1.2m
Depreciation, Depletion and Amortization $12.0m $12.6m $14.5m $7.1m $9.0m $10.2m $12.6m $25.7m $28.2m $31.6m $64.7m
Depreciation $12.0m $12.6m $14.5m $17.1m $20.5m $22.2m $23.8m $25.2m $28.2m $31.6m $39.6m
Amortization of Debt Issuance Costs $219k $466k $11.4m $6.0m $3.4m
Amortization of Intangible Assets $2.5m $2.9m $2.0m $1.0m $1.0m $1.3m $1.4m $12.8m $24.7m $25.0m
Capitalized Computer Software, Amortization $0
Deferred Income Tax Expense (Benefit) ($4.0m) $2.7m ($4.4m) $7.5m $917k $3.7m ($15.9m) ($13.9m) ($17.1m) $28.7m $27.6m
Share-based Payment Arrangement, Noncash Expense $15.1m $17.1m $16.7m $17.3m $20.5m $18.7m $17.9m $20.2m $24.4m $27.3m $28.9m
Share-based Payment Arrangement, Expense $15.1m $17.1m $16.7m $17.3m $20.5m $18.7m $17.9m $20.2m $24.4m $27.3m $28.9m
Income (Loss) from Equity Method Investments ($208k) ($1.2m) ($2.0m) ($573k)
Nonoperating Income (Expense) ($746k) $2.5m ($1.3m) $60.3m ($6.3m) $14.3m $8.5m ($25.6m) ($15.7m) ($16.8m)
Other Nonoperating Income (Expense) $8k $2.9m ($1.5m) $59.4m ($6.6m) $14.5m $9.1m ($3.9m) $4.1m $23k
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable ($6.4m) $8.1m $16.3m ($6.7m) $20.2m $14.9m $10.1m $26.1m $21.7m $6.4m ($12.1m)
Increase (Decrease) in Inventories $9.7m ($18.6m) $6.0m $41.1m ($15.3m) ($1.3m) $11.7m $1.7m $48.8m $21.1m $11.2m
Inventory Write-down $8.5m $12.9m $9.4m $13.9m $24.6m $17.2m $18.8m $14.0m $6.0m
Net Cash Provided by (Used in) Operating Activities $38.6m
$39.2m +1.68%
$38.2m -2.60%
$41.8m +9.35%
$57.3m +37.12%
$98.0m +71.12%
$89.2m -8.99%
$183.5m +105.76%
$213.4m +16.28%
$156.1m -26.84%
$184.6m +18.25%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $21.4m $35.1m $46.8m $41.6m $33.9m $27.5m $24.0m $38.2m $41.0m $34.9m ($31.7m)
Gain (Loss) on Disposition of Property Plant Equipment ($1.2m) $2.3m ($1.4m) $17.1m $20.5m $22.2m $23.8m $25.2m $28.2m $31.6m ($519k)
Restricted Cash and Investments, Current $4.2m $4.2m
Net Cash Provided by (Used in) Investing Activities ($39.5m) ($38.8m) ($42.2m) ($50.5m) ($36.4m) ($28.7m) ($32.8m) ($649.1m) ($124.9m) ($70.3m) ($52.1m)
Cash flows from financing activities:
Repayments of Long-term Debt $14.7m $9.7m $5.7m $6.4m $8.4m $36.7m $1.8m $318.7m $8.3m $223k ($702k)
Proceeds from Issuance of Long-term Debt $10.2m $19.0m $8.4m $3.6m $6.3m $70.0m $845.0m $445k
Payments for Repurchase of Common Stock $9.9m $30.7m $25.0m $22.3m $24.4m $28.9m $39.9m $58.1m $85.5m $75.6m
Net Cash Provided by (Used in) Financing Activities $7.1m
($7.7m) -208.10%
$25.0m +424.02%
($3.8m) -115.13%
($2.2m) +40.63%
($37.0m) -1548.17%
($26.4m) +28.58%
$454.1m +1817.51%
($81.0m) -117.83%
($67.4m) +16.71%
($96.5m) -43.07%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect ($4.9m) $20.7m ($12.7m) $19.0m $32.1m $29.7m ($11.8m) $7.3m $18.6m $224.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($4.9m) $88.2m $75.5m $94.5m $126.6m $156.3m $144.5m $151.8m $170.4m $224.0m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $81k $504k ($274k) ($104k) $352k ($223k) ($220k) ($282k) ($190k) $210k ($172k)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $20.3m $19.1m $11.8m $7.8m $24.4m $16.8m $19.2m $14.2m $12.2m $6.4m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.7m $1.9m $2.4m $2.4m $2.2m $2.1m $3.0m $17.6m $26.8m $23.2m
Income Taxes Paid, Net $3.4m $4.9m $339k $5.7m $3.4m $8.1m $44.4m $49.0m $40.1m $22.7m
Additional Financial Items
Accretion Expense $72k
Deconsolidation, Gain (Loss), Amount $13.6m
Gain (Loss) on Disposition of Assets ($1.0m) ($240k) ($348k) ($141k) ($475k) ($9k) ($39k)
Gain (Loss) on Disposition of Intangible Assets $2.6m
General and Administrative Expense $41.8m $44.5m $49.9m $50.3m $50.4m $51.4m $45.1m $51.5m $56.7m $85.9m
Goodwill $4.0m $4.5m $4.0m $3.6m $3.9m $3.3m $3.1m $3.2m $3.0m $3.4m $0
Income Tax Expense (Benefit) $4.4m ($2.9m) ($3.3m) $13.7m $3.5m $20.6m $23.5m $31.8m $29.7m $25.5m
Interest Expense Nonoperating $30.3m $25.5m
Investment Income, Interest $270k $425k $456k $997k $642k $601k $1.3m $5.5m $10.6m $8.7m
Operating Expenses $88.5m $91.7m $115.6m $132.0m $132.4m $129.9m $141.4m $154.1m $168.4m $215.7m
Pension Cost (Reversal of Cost) $200k $200k $300k $200k $200k $200k $0 $0